Immunome, Inc.
IMNM
$5.56
-$0.32-5.44%
| Weiss Ratings | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.62 | |||
| Price History | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -20.46% | |||
| 30-Day Total Return | -42.50% | |||
| 60-Day Total Return | -47.55% | |||
| 90-Day Total Return | -50.13% | |||
| Year to Date Total Return | -47.20% | |||
| 1-Year Total Return | -72.39% | |||
| 2-Year Total Return | 2.96% | |||
| 3-Year Total Return | 10.32% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -72.93% | |||
| 52-Week Low % Change | 9.91% | |||
| Price | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $21.72 | |||
| 52-Week Low Price | $5.35 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Apr 15, 2024 | |||
| Valuation | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 511.27M | |||
| Enterprise Value | 298.80M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.18 | |||
| Earnings Per Share Growth | 55.64% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 40.89 | |||
| Price/Book (Q) | 2.09 | |||
| Enterprise Value/Revenue (TTM) | 33.05 | |||
| Price | $5.56 | |||
| Enterprise Value/EBITDA (TTM) | -1.97 | |||
| Enterprise Value/EBIT | -1.95 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 62.84M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 425 939 7410 | |||
| Address | 18702 N. Creek Parkway Bothell, WA 98011 | |||
| Website | immunome.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,697.33% | |||
| Profit Margin | -3,240.38% | |||
| Management Effectiveness | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -49.34% | |||
| Return on Equity | -- | |||
| Income Statement | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.04M | |||
| Total Revenue (TTM) | 9.04M | |||
| Revenue Per Share | $0.14 | |||
| Gross Profit (TTM) | -120.50M | |||
| EBITDA (TTM) | -151.89M | |||
| EBIT (TTM) | -153.46M | |||
| Net Income (TTM) | -292.96M | |||
| Net Income Avl. to Common (TTM) | -292.96M | |||
| Total Revenue Growth (Q YOY) | -28.44% | |||
| Earnings Growth (Q YOY) | 13.37% | |||
| EPS Diluted (TTM) | -5.18 | |||
| EPS Diluted Growth (Q YOY) | 40.84% | |||
| Balance Sheet | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 217.30M | |||
| Cash Per Share (Q) | $3.46 | |||
| Total Current Assets (Q) | 221.34M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 181.17M | |||
| Current Ratio (Q) | 4.076 | |||
| Book Value Per Share (Q) | $2.81 | |||
| Total Assets (Q) | 240.24M | |||
| Total Current Liabilities (Q) | 54.31M | |||
| Total Debt (Q) | 4.83M | |||
| Total Liabilities (Q) | 59.08M | |||
| Total Common Equity (Q) | 181.17M | |||
| Cash Flow | IMNM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -85.06M | |||
| Cash from Financing (TTM) | 240.53M | |||
| Net Change in Cash (TTM) | 44.67M | |||
| Levered Free Cash Flow (TTM) | -100.33M | |||
| Cash from Operations (TTM) | -110.79M | |||
